In this report, we now demonstrate that lower ASPP2 mRNA and protein expression levels are statistically significantly associated with clinical unfavorable disease and early chemotherapy-induction failure in de novo as well as secondary acute myeloid and lymphoid leukemia. This evidence concerns the gene TP53BP2 and lymphoid leukemia.